PHAT - Phathom Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
24.27
-1.60 (-6.18%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close25.87
Open25.75
Bid24.27 x 1000
Ask23.94 x 1000
Day's Range24.27 - 26.72
52 Week Range20.26 - 28.51
Volume51,361
Avg. Volume136,750
Market Cap668.58M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Phathom Pharmaceuticals to Present at Jefferies 2019 London Healthcare Conference

    Phathom Pharmaceuticals, Inc. , a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that David Socks, President and CEO, will present at the Jefferies 2019 London Healthcare Conference on Wednesday, November 20 at 10:40 a.m.

  • Business Wire

    Phathom Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    Phathom Pharmaceuticals, Inc. , a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the closing of its previously announced initial public offering of 10,997,630 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 1,434,473 additional shares, ...

  • Bloomberg

    Phathom Pharmaceuticals Rises Almost 30% After $182 Million

    (Bloomberg) -- Phathom Pharmaceuticals Inc. rose 29.5% after expanding its initial public offering to raise $182 million, adding to a wave of biomedical and biotechnology going public.Shares of Phathom closed at $24.60 in first day of trading Friday, giving the company a market value of $678 million.Phathom, based in Buffalo Grove, Illinois, sold 9.56 million shares for $19 each on Thursday. The company earlier had marketed 7.9 million shares for $18 to $20.The listing is one of 38 by biotechnology or biomedical companies on U.S. exchanges this year. While those IPOs have accounted for only $5.3 billion of the total $47 billion raised, they made up about a quarter of the 156 listings, according to data compiled by Bloomberg.Cabaletta Bio Inc., which is developing treatments for autoimmune diseases, raised $75 million in its IPO Thursday. It priced its shares at $11, below the target range of $14 to $16. They closed at $10 on Friday.Phathom is focused on commercializing novel treatments for gastrointestinal diseases. The company lost $89 million in the six months ended June 30, according to its filings with the U.S. Securities and Exchange Commission.Its offering was led by Goldman Sachs Group Inc., Jefferies Financial Group Inc. and Evercore Inc. Its shares are trading on the Nasdaq Global Market under the symbol PHAT.(Updates with closing share price in second paragraph)To contact the reporter on this story: Michael Hytha in San Francisco at mhytha@bloomberg.netTo contact the editors responsible for this story: Liana Baker at lbaker75@bloomberg.net, Michael Hytha, Matthew MonksFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Business Wire

    Phathom Pharmaceuticals Announces Pricing of Initial Public Offering

    Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it has priced its initial public offering of 9,563,157 shares of its common stock at a public offering price of $19.00 per share. The gross proceeds to Phathom, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $181.7 million. All of the common stock is being offered by Phathom.